Search

Displaying results 6131 - 6140 of 7499 in total
  1. Drug

    Recanaclotide

    go.drugbank.com/drugs/DB15417
    Investigational

    Recanaclotide is under investigation in clinical trial NCT01712412 (Phase 2a Study of IW-9179 to Treat Functional Dyspepsia).

  2. Drug

    Ethyl butyrate

    go.drugbank.com/drugs/DB15454
    Experimental

    Ethyl butyrate is under investigation in clinical trial NCT03202342 (fMRI of Hypothalamic Responses to Taste, Temperature and Glucose).

  3. Drug

    Buprenorphine hemiadipate

    go.drugbank.com/drugs/DB16117
    Investigational

    Buprenorphine hemiadipate is under investigation in clinical trial NCT01582347 (Transfer of Subjects From Subutex/suboxone to RBP-6300).

  4. Drug

    Solrikitug

    go.drugbank.com/drugs/DB19301
    Investigational

    Solrikitug is under investigation in clinical trial NCT06496607 (A Study to Evaluate Solriktug in Adult Participants With Asthma).

  5. Drug

    ATL1101

    go.drugbank.com/drugs/DB05023
    Experimental

    ATL1101 is being developed as a cream for the topical treatment of mild to moderate cases of psoriasis. … ATL1101 is a second-generation antisense drug designed to block the synthesis of the IGF-1 receptor, a protein involved in the regulation of cell overgrowth in psoriasis.

  6. Drug

    VB2-011

    go.drugbank.com/drugs/DB05411
    Experimental

    According to some preclinical studies, it has a potential to inhibit tumour growth in various cancers including lymphoma and melanoma.

  7. Drug

    Sparfosic acid

    go.drugbank.com/drugs/DB03459
    Experimental

    This compound belongs to the n-acyl-alpha amino acids. These are compounds containing an alpha amino acid which bears an acyl group at the terminal nitrogen atom. … This substance is known to target aspartate carbamoyltransferase catalytic chain and CAD protein.

    Synonyms: N-(phosphonacetyl)-L-aspartic acid, N-phosphonacetyl-L-aspartic acid
  8. Drug

    VY-HTT01

    go.drugbank.com/drugs/DB16999
    Investigational

    VY-HTT01 is a gene therapy designed to reduce the expression of huntingtin, thereby altering disease progression. … VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses the canonical RNA interference pathway to selectively knock down levels of HTT mRNA.

  9. Drug

    UDP-alpha-D-glucuronic acid

    go.drugbank.com/drugs/DB03041
    Experimental

    It may also be epimerized to UDP iduronic acid, which donates iduronic acid to polysaccharides. In animals, UDP glucuronic acid is used for formation of many glucosiduronides with various aglycones.

  10. Drug

    Linseed oil

    go.drugbank.com/drugs/DB11357
    Investigational

    Linseed oil is particularly susceptible to polymerization reactions upon exposure to oxygen in air due to a high content of di- and triunsaturated esters.